Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs and Low-Dose IL-2 in Metastatic Melanoma
NCT01883323Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jun 2013
- Primary completion
- Apr 2018
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by University Health Network. Started Jun 2013; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01883323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883323.